MIdWestOne Financial Group Inc. boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 13.3% in the 4th quarter, Holdings Channel reports. The firm owned 10,704 shares of the biotechnology company’s stock after buying an additional 1,258 shares during the period. MIdWestOne Financial Group Inc.’s holdings in United Therapeutics were worth $5,216,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the fourth quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on UTHR. Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.
United Therapeutics Price Performance
UTHR opened at $545.40 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market capitalization of $23.15 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The company has a fifty day moving average price of $567.24 and a 200-day moving average price of $521.17.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $6.63 earnings per share. On average, analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current year.
Insider Activity at United Therapeutics
In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 624,984 shares of company stock worth $352,682,302 over the last ninety days. Corporate insiders own 8.60% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
